Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

About this trial

The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis for selecting suitable populations for precise tumor treatment and corresponding therapy. We retrospectively analyzed patient case data, extracted preoperative CT images, H\&E-stained whole-slide digital pathology images, and pre- or postoperative genetic testing reports to extract radiomic features of tumor and peritumoral regions. These features were combined with multidimensional pathological features and gene expression distribution characteristics to construct a multimodal radiopathogenomic model, offering more precise prognostic evaluation for lung cancer patients receiving targeted therapy.

Eligibility criteria

Qualifiers

Age 18-80 years, undergoing radical surgery for lung cancer (R0 resection);

Postoperative pathological stage IB-IIIA, pathology confirmed as adenocarcinoma;

EGFR gene testing positive, EGFR 19del/L858R mutation;

Receiving postoperative EGFR-TKI targeted adjuvant therapy;

Disqualifiers

Patients negative for EGFR;

Incomplete surgical resection (R1, R2);

Did not receive EGFR-TKI targeted therapy after surgery;

Recurrent or advanced stage patients;

Trial design

Treatments tested in this trial

  • Comprehensive analysis through laboratory tests, imaging techniques, and clinical data

Treatment groups

No treatment groups listed